The company, after revealing in May that it was evaluating various partnership or buyout strategies, also said it would sell its IL-6 programs to Roche as it pauses Vicineum’s US development.
Sesen Bio, Inc. is selling off a portfolio of anti-interleukin-6 (IL-6) antibodies to collaborator Roche Holding AG and looking to find a partner for its lead oncology asset, Vicineum, which was the subject of a complete response letter in 2021, with an eye toward saving money as the company maps out a new strategy following a meeting with the US Food and Drug Administration.
Sesen said on 18 July that it would pause further development of Vicineum (oportuzumab monatox) in the US after what...
Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
Coartem Baby to be rolled out in eight African countries in the autumn.
